Iolyx Therapeutics, a California-based clinical-stage biopharmaceutical company, has entered a strategic collaboration with European ophthalmology leader Laboratoires Théa.
The agreement, valued at up to $280 million plus tiered royalties, centers on ILYX-002, Iolyx’s lead candidate for treating autoimmune-associated dry eye disease. Concurrently, Iolyx announced a $15 million Series B financing round to advance its broader pipeline.
Under the terms, Théa will assume responsibility and costs for global Phase III clinical development and commercialization of ILYX-002, excluding Asian markets. Iolyx will retain oversight of clinical trial design and manufacturing. The partnership aims to leverage Théa’s extensive late-stage development expertise and worldwide commercial network to accelerate the potential delivery of the therapy to patients.
ILYX-002: Targeting the Underlying Autoimmune Driver
ILYX-002 is a novel, investigational topical eye drop designed as a potent and highly selective inhibitor of the enzyme receptor-interacting serine/threonine-protein kinase 1 (RIPK1). This mechanism targets a key pathway in necroptosis, a form of inflammatory cell death implicated in the pathogenesis of autoimmune and inflammatory disorders.
The drug is specifically targeted for the subset of dry eye disease patients with underlying autoimmune dysfunction, such as those with Sjögren’s syndrome or rheumatoid arthritis. This population often experiences more severe symptoms and has limited effective treatment options beyond palliative care.
The partnership follows promising Phase II clinical results announced by Iolyx in May 2025. The randomized, double-masked, vehicle-controlled study evaluated ILYX-002 in patients with moderate-to-severe dry eye disease and documented systemic autoimmunity.
According to the earlier release, the trial met its primary endpoint, showing a statistically significant improvement in corneal fluorescein staining (CFB) at Day 57 compared to vehicle. Notably, improvements were observed as early as Day 8 and were sustained throughout the treatment period.
Key secondary endpoints, including reduction in dry eye symptoms as measured by the Ocular Surface Disease Index (OSDI), also showed positive trends favoring ILYX-002. The treatment was reported to be well-tolerated with a favorable safety profile.
“Patients with autoimmune-associated dry eye represent a population with a significant unmet need, often facing more persistent and severe disease,” said Jean-Frédéric Chibret, President of Laboratoires Théa. “We are impressed with the Phase II data for ILYX-002 and believe its targeted mechanism has the potential to meaningfully alter the treatment paradigm.”
Funding Fuels Pipeline Expansion into Retinal Diseases
The concurrent $15 million Series B financing, led by existing investors, provides capital to expand Iolyx’s research initiatives. Beyond the dry eye program, the company plans to advance its pipeline into autoimmune-associated retinal diseases, exploring applications of its RIPK1 inhibition platform for conditions like uveitis and other sight-threatening inflammatory retinal disorders.
“The agreement with Théa validates our science and provides the resources to execute a global Phase III program for ILYX-002, while the Series B allows us to broaden our impact to the back of the eye,” stated Stephen Smith, CEO of Iolyx Therapeutics.
The companies anticipate initiating Phase III studies for ILYX-002 in autoimmune-associated dry eye disease in the ‘near future’, following regulatory consultations.
